Mederi Therapeutics grabbed $18.5 million in new financing to back an expanded commercial push for treatment devices that address gastroesophageal reflux disease and bowel incontinence. Acadia Woods Partners, Respiratory Diagnostics (a Bio-Rad Laboratory subsidiary) and a number of high-net-worth equity investors participated in the Series B financing, which involved preferred stock and venture debt. Greenwich, CT-based Mederi makes and sells medical devices that use radiofrequency energy to treat digestive system-related diseases. Item